Crizotinib in the treatment of non-small-cell lung cancer
Carcinoma, Non-Small-Cell Lung
Protein Kinase Inhibitors
Crizotinib represents the newest example of a focused strategy for drug development in lung cancer, based on identification and targeted inhibition of critical tumor-specific driver mutations. Crizotinib has demonstrated efficacy against ALK-rearranged NSCLC, and has potential for broader application in select subsets of lung cancer.